Trispecific antibodies for cancer immunotherapy
Immunology · 2023-08 · 169 (4) · 389-399
DOI: 10.1111/imm.13636 ↗At a glance
Übersichtsarbeit in Immunology, published online on 2023-03-08. Written by Yin Yao and 2 co-authors. Institution: Department of Pharmacy, Fourth People's Hospital of Gui Yang, Guiyang, China. Major MEDLINE topics: Antibodies, Bispecific, Neoplasms. Cited 40 times so far (Crossref); 67 references.
Abstract (original language)
Despite the clinical success of monoclonal and bispecific antibodies, there are still limitations in the therapeutic effect of malignant tumours, such as low response rate, treatment resistance, and so on, inspiring the exploration of trispecific antibodies (TsAbs). TsAbs further improve the safety and efficacy and has great clinical potential through three targets combination and formats optimization. This article reviews the development history and the target combination features of TsAbs. Although there are still great challenges in the clinical application of TsAbs, it is undeniable that TsAbs may be a breakthrough in the development of antibody drugs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Fourth People's Hospital of Gui Yang, Guiyang, China.
- Department of Nursing, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
ORCID profiles: Fei Wang
Cite
APA
Yao, Y., Hu, Y., & Wang, F. (2023). Trispecific antibodies for cancer immunotherapy. Immunology, 169(4), 389-399. https://doi.org/10.1111/imm.13636
Vancouver
Yao Y, Hu Y, Wang F. Trispecific antibodies for cancer immunotherapy. Immunology. 2023;169(4):389-399. doi:10.1111/imm.13636
BibTeX
@article{Yao2023,
author = {Yao, Yin and Hu, Yiyin and Wang, Fei},
title = {Trispecific antibodies for cancer immunotherapy},
journal = {Immunology},
year = {2023},
volume = {169},
number = {4},
pages = {389--399},
doi = {10.1111/imm.13636}
}
EUVIMED